Deep Track Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

Deep Track Capital’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$65M	Sell	1,150,000 -1,150,000	-50%	-$67.1M	1.06%	27
2025 Q4	$137M	Buy	2,300,000 +2,275,144	+9,153%	+$124M	2.44%	13
2025 Q3	$1.35M	Buy	+24,856	New	+$1.42M	0.04%	54
2023 Q1	–	Sell	-189,800	Closed	-$19.6M	–	63
2022 Q4	$19.6M	Sell	189,800 -549,063	-74%	-$51.5M	0.82%	39
2022 Q3	$62.6M	Buy	738,863 +84,498	+13%	+$7.52M	2.87%	10
2022 Q2	$54.2M	Buy	+654,365	New	+$52.1M	3.56%	9

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Deep Track Capital's BMRN Position: Q1 2026 in Review

Deep Track Capital reduced its BioMarin Pharmaceuticals (BMRN) stake by 50% in Q1 2026, selling an estimated $67.1M and leaving 1,150,000 shares worth $65M. The position accounts for 1.06% of the portfolio, ranked #27.

Deep Track Capital first reported a position in BMRN in Q2 2022 and has held it in 6 quarters since. The position peaked at $137M in Q4 2025. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

Deep Track Capital held 1,150,000 shares of BioMarin Pharmaceuticals worth $65M as of Q1 2026.
Deep Track Capital sold 1,150,000 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $67.1M.
BioMarin Pharmaceuticals made up 1.06% of Deep Track Capital's portfolio in Q1 2026, its #27 holding.
Deep Track Capital first reported a position in BioMarin Pharmaceuticals in Q2 2022 and has held it in 6 quarters since.
Deep Track Capital's BioMarin Pharmaceuticals position peaked at $137M in Q4 2025.
554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Deep Track Capital's 13F filing for Q1 2026, filed 15 May 2026.